Pomalyst can cause certain adverse effects (side effects), some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. But if the side effects last ...

Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. In the United States, Pomalyst is used to treat multiple myeloma patients who have gone through at ...

The trial evaluated Pomalyst in combination with low-dose dexamethasone versus high-dose dexamethasone in relapsed and refractory multiple myeloma (MM) patients, who have received unsuccessfully at ...

A New York City federal court has dismissed a proposed class-action lawsuit against Bristol Myers Squibb that accused the drugmaker of deploying anticompetitive tactics to protect the market ...

Defying critics in Congress and elsewhere, Celgene hiked the list prices of key cancer meds Revlimid and Pomalyst by 9% this month, taking their cumulative increases for the year to nearly double the ...

NEW YORK, June 24 (Reuters) - Cigna (CI.N), opens new tab sued Bristol Myers Squibb (BMY.N), opens new tab on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

The Food and Drug Administration approved Pomalyst (pomalidomide) on Feb. 8 to treat patients with multiple myeloma who have progressed during or within 60 days after receiving at least two therapies, ...

(Reuters) - Bristol Myers Squibb has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst for years ...

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to POMALYST® ...

Its parent has one of the longest and varied histories in the annals of medicine. Its sibling is a star raking in billions of dollars every year. And now it stands ready to take the stage on its own.